Better Tests, Better Answers 

Jyotsna Shah, PhD, Ticktective

Bay Area Lyme Leading the Way Series

 

“The IGeneX test is far more sensitive than most commercially available tests for Lyme disease, detecting far more positive patients compared to standard two-tier ELISA or Western Blot tests,”

– Jyotsna Shah, PhD

Click here to watch or listen now

For people living with or who suspect Lyme disease, getting a clear diagnosis can feel like the hardest part. Symptoms often mimic those of other illnesses, and traditional tests miss many cases. 

In this episode of Ticktective™, Dr. Jyotsna Shah, President and Laboratory Director of IGeneX, shares with our host, Dana Parish, how her team is changing that—and how Bay Area Lyme Foundation helped make it possible. 

Dr. Shah explains how partnerships between innovative labs like IGenex, Bay Area Lyme Foundation, and our Lyme Disease Biobank are helping deliver faster, more accurate diagnostics—and new hope for patients who’ve struggled for years to find answers.

Ten Years of Data, One Clear Message: We Need to Do Better for Lyme Patients

Lyme Disease Biobank

Bay Area Lyme Leading the Way Series

By Liz Horn, PhD, MBI, Principal Investigator, Lyme Disease Biobank

“The window for effective antibiotic treatment is narrow. Miss it—because of a false negative test, because symptoms are dismissed, or because follow-up doesn’t happen—and patients can develop persistent Lyme, which can be debilitating.”

– Dr. Liz Horn

Lyme Disease Biobank patient sample

After a decade of collecting blood samples, testing the samples, tracking patient outcomes, and analyzing data from more than 800 participants, the numbers tell a powerful story about the gaps in our understanding of how we diagnose and treat early Lyme disease. And it’s made all the more urgent by this summer’s explosion in blacklegged (deer) tick populations across endemic areas.

Our latest Lyme Disease Biobank study looked at more than 250 patients with early Lyme disease on Long Island and in Central Wisconsin who provided a blood draw at enrollment and a second blood draw three months later. Published recently in Frontiers in Medicine, these 10 years of data confirm a few important points that have been known in the Lyme field for years, but the wider medical community may not be aware of.

LymeLnk and Bay Area Lyme Foundation Partner to Bridge the Gap Between Research and Public Awareness

LymeLnk

Bay Area Lyme Leading the Way Series

 

“Science moves minds and stories move hearts. This partnership connects two essential parts of the Lyme ecosystem: the research that advances medicine and the communication that inspires action. Together, we’re making education and prevention more accessible.” 

– Eva Scarano, Founder and Executive Director, LymeLnk

LymeLnk is a new nonprofit combating Lyme and tick-borne diseases (Lyme+) through community storytelling and education. Founded in 2024 at Parsons School of Design, LymeLnk was born out of founder Eva Scarano’s personal nine-year journey with Lyme+, during which she chose to create meaning from her isolated quest for health.

Eva’s Lyme+ journey began in 2016 with a textbook case: a bull’s-eye rash and flu-like symptoms. Among the fortunate few to receive a prompt diagnosis, she underwent three grueling months of antibiotics and supplemental treatment and was asymptomatic for two years. Everything changed in 2019 when she moved into a mold-infested apartment, triggering a collapse of her immune system—her Lyme markers were back and higher than ever. Years later, Eva had just begun graduate school at Parsons when she found herself at her “rock bottom.” Struggling to remember class material from the day prior or make it past 3:00 pm without a nap, she remained determined to continue her studies and reclaim her health.

Chronic Infections, Fertility, & Immunity: MIT Immunoengineer Makes Groundbreaking Lyme Discoveries

Michal Caspi Tal, PhD

Bay Area Lyme Spotlight Series

 

“There are significant increases after Lyme in fibroids and in endometriosis.”

– Michal Caspi Tal, PhD

Dancing Borrelia, Mikki Tal, PhD
Borrelia burgdorferi under attack from the immune system.

Imagine a world where Lyme disease isn’t something people fear, but something we actively prevent, or at least treat more precisely, especially for the many who suffer long after the tick bite. Dr. Michal “Mikki” Caspi Tal, immunoengineer and Associate Scientific Director at the MIT Center for Gynecology Pathology Research, is turning that possibility into reality. Her research isn’t just pushing boundaries, it’s rewriting the rules, especially in regards to women’s health.

“Nobody had looked…at what was happening to the uterus.”

– Michal Caspi Tal, PhD

Watching this incredible Ticktective™ interview with host Dana Parish is an absolute treasure trove of information—and if you or someone you know has ever wondered why some people recover from Lyme and others don’t, why symptoms linger, or why women disproportionately suffer, this is one of the most important conversations you’ll hear this year.

Click here to watch or listen now

Progress from Partnership: Reflections from the Frontlines

Meghan Bradshaw

Bay Area Lyme Leading the Way Series

Guest blog by Lyme Advocate, Meghan Bradshaw, Government Relations Manager, Center for Lyme Action

“Bay Area Lyme Foundation’s leadership, fundraising, and commitment to research and patient advocacy have been a bedrock.” 

– Meghan Bradshaw

When I look back over the past few years, I’m struck by how much has changed—for me personally, and for the broader Lyme and tick-borne disease community. And perhaps most of all, I see how partnership and persistence have turned what once felt impossible into genuine progress.

Turning Pain into Purpose as a Living Donor

Lyme Disease Biobank

One of the most powerful examples of Bay Area Lyme’s impact is Lyme Disease Biobank—a groundbreaking resource that provides researchers with high-quality, well-characterized samples to accelerate discoveries in diagnostics and treatment.

I know firsthand what it means to contribute to that effort—with my own body. As a living donor, I’ve donated multiple joints to the Biobank following joint replacement surgeries. It was, without exaggeration, a painful process. But I did it because I believe in turning my suffering into solutions—knowing that those tissues may one day help someone else get diagnosed sooner or treated more effectively.

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease

FOR IMMEDIATE RELEASE

 

Journal of Clinical Microbiology Studies Demonstrate Two Investigational Diagnostics Outperform Current Tests in Detecting Early Lyme Disease

Studies utilize Bay Area Lyme Foundation’s Lyme Disease Biobank samples to point to the promise of single-tier diagnostics to potentially transform early detection

 

PORTOLA VALLEY, Calif., October 9, 2025 — Bay Area Lyme Foundation, the leading nonprofit funder of Lyme disease research in the US, today announced results from two independent studies published in Journal of Clinical Microbiology, conducted by researchers at Tufts University School of Medicine, and Kephera Diagnostics, respectively, demonstrating the potential of novel investigational single-tier Lyme disease tests to improve accuracy in the earliest stages of infection. Each study uses well-characterized samples from Bay Area Lyme Foundation’s Lyme Disease Biobank and demonstrated unprecedented accuracy, far exceeding the current CDC-recommended Lyme disease two-tier test, which can miss up to 70% of early-stage cases as well as later-stage cases.

“The CDC’s standard two-tier Lyme diagnostic misses the majority of early cases, delaying treatment and increasing the risk of developing persistent, debilitating symptoms for patients. The two novel single-tier assays—while not yet FDA-cleared for clinical use—point to a future where Lyme disease can be diagnosed quickly, accurately, and with a single test,” Liz Horn, PhD, MBI, a coauthor on both studies, and Principal Investigator of Lyme Disease Biobank, a Bay Area Lyme Foundation program that provides much-needed samples to approved researchers working to better understand tick-borne diseases and develop improved diagnostic tests and therapeutics. “These single tier tests, like InBios Lyme Detect™ and Kephera’s Hybrid Lyme ELISA could mark a turning point for Lyme diagnostics, giving physicians and patients more accurate tools that are urgently needed.”

The first study, evaluating the InBios Lyme Detect™ Multiplex ELISA, was conducted by Pete Gwynne, PhD, a 2022 Bay Area Lyme Emerging Leader Award (ELA) winner, and colleagues at Tufts University School of Medicine. Using samples from the Lyme Disease Biobank, this new diagnostic correctly identified all two-tier positive samples evaluated in the study, while also detecting 21 of 79 clinically diagnosed patients who were missed by following the current CDC guidance for testing using FDA-cleared standard two-tier tests (STTT) and had erythema migrans (EM) skin lesions. Importantly, the InBios test maintained >99% specificity, with only one false positive across more than 200 control and lookalike disease samples and was shown to be highly reproducible.

Dr. Joe Burrascano: A Masterclass on Tick-Borne Illness

Dr Joe Burrascano

Ticktective Podcast Transcript

In this episode of Ticktective™, host Dana Parish interviews Joe Burrascano, MD. Dr. Burrascano is a pioneer in the field of Lyme disease, having treated patients since the early days of the illness in the 1980s and 1990s. He co-founded the International Lyme and Associated Diseases Society (ILADS) to help train clinicians in treating Lyme and associated tick-borne diseases. Dr. Burrascano discusses the challenges in diagnosing and treating Lyme, including issues with the limited testing criteria and the chronic, multisystemic nature of the disease. He outlines his approach to treating early Lyme with a “hybrid” antibiotic regimen, as well as the use of pulsed and cycling antibiotic therapies for chronic cases. He also highlights the importance of addressing underlying health factors like immune dysfunction, toxin buildup, and co-infections like Bartonella and mold toxicity in chronic Lyme patients. Dr. Burrascano emphasizes the need for a holistic, patient-centered approach to managing complex, persistent tick-borne illnesses.

“If you have something that’s every part of your body is bothering you, and it comes and goes and it moves around, of course, you’re going to be labeled as a little bit cuckoo. It’s not. It’s Lyme disease.”

– Joe Burrascano, MD

Dana Parish: Welcome to the Ticktective Podcast, a program of the Bay Area Lyme Foundation, where our mission is to make Lyme disease easy to diagnose and simple to cure. I’m your host, Dana Parish, and I’m the co-author of the book Chronic, and I sit on the advisory board of Bay Area Lyme Foundation. This program offers insightful interviews with scientists, clinicians, patients, and other interesting people. We’re a nonprofit based in Silicon Valley, and thanks to a generous grant that covers a hundred percent of our overhead, all of your donations go directly to our research and prevention programs. For more information about Lyme disease, please visit us@bayarealyme.org.

Justin Timberlake’s Lyme Diagnosis and His Struggle to Be Believed

Justin Timberlake

Bay Area Lyme Spotlights Series

 

Medical skepticism isn’t just cruel, it’s physically, mentally, and emotionally harmful.

When Justin Timberlake revealed his Lyme disease after weeks of criticism for low-energy performances during his recent tour, the Internet did what the Internet does: It immediately questioned whether he was telling the truth.

The skepticism was rife and merciless. Reddit threads quickly surfaced with accusations that he was making excuses, faking illness, or using Lyme as a convenient cover story. “There must be something else going on,” people assumed. “Chronic Lyme isn’t a thing,” they said.

While it’s almost expected to see anonymous Internet commenters take aim at a major celebrity going through a low point, for the millions of Americans living with Lyme disease, Timberlake’s experience is not surprising at all.

Teaching Kids to Protect Themselves from Tick Bites 

Melissa Kelly at Chartwell School

Bay Area Lyme Spotlights Series

 

“Lyme and ticks are talked about a lot more! Students are showing peers their tick keys and sharing information, and even staff are discussing it around campus.”

– Melissa Kelly, teacher

Oliver, 9th Grade
Oliver, 9th Grade

Children are the most at-risk group for contracting tick-borne diseases, so Monterey Peninsula health educator, Melissa Kelly, gave her students an important assignment during Lyme Disease Awareness month: design a poster to teach their school community about Lyme and tick-borne diseases and how to prevent tick bites. Bay Area Lyme Foundation provided tick keys and educational materials to support Melissa’s teaching and curriculum. We asked Melissa to tell us about the project!

Q: Melissa, tell us about your school, where it’s located, and how you learned about Lyme disease awareness month.

A: Chartwell School is located in Seaside, California. We serve students with learning differences such as dyslexia and more. Our school community includes students from 1st to 12th grade. I work specifically with high school students. I first learned about Lyme Disease Awareness Month after my own experience with Lyme disease. Before teaching, I worked as a field biologist and likely contracted Lyme during my fieldwork. Thankfully, I was able to get it treated, and I am okay. That experience has kept me engaged with the latest research and studies on tick-borne diseases, which is how I learned about Lyme Awareness Month.

New Bay Area Lyme Foundation Study Reports That Only One-Third of Early Lyme Patients with On-Going Symptoms Followed up with their Healthcare Providers

Lyme Disease Biobank

FOR IMMEDIATE RELEASE

 

New Bay Area Lyme Foundation Study Reports That Only One-Third of Early Lyme Patients with On-Going Symptoms Followed up with their Healthcare Providers

The new research, published in Frontiers in Medicine, points to need for greater follow-up from medical professionals to address potential treatment failures. 

PORTOLA VALLEY, Calif., July 10, 2025—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announced the publication of new research in Frontiers in Medicine based on data from Bay Area Lyme Foundation’s Lyme Disease Biobank. This large-scale study conducted over 10 years at sites on the East Coast and the Upper Midwest demonstrates the need for improved diagnostics and increased follow-up by medical professionals for Lyme disease patients.

Only one-fifth of study participants (23%), enrolled with signs and symptoms of early Lyme, were positive by the CDC’s standard two-tiered test for Lyme disease, which supports previous research that found that it misses up to 70% of cases of early-stage Lyme disease. Further, approximately 1 in 5 patients reported ongoing symptoms at 3 months, including joint pain, fatigue, and muscle pain yet only one-third (35%) of these participants followed up with their healthcare providers about these ongoing symptoms. Due to difficulties in diagnosing Lyme disease and resulting treatment delays, as many as two million people may suffer from persistent Lyme disease, which can be debilitating.

Accurate, timely detection of Lyme disease is critical to preventing long-term complications. Moreover, follow-up from medical professionals with all patients after they complete antibiotic treatment could improve outcomes and reduce the burden of Lyme disease,” said lead author Liz Horn, PhD, MBI, Principal Investigator of Lyme Disease Biobank, a Bay Area Lyme Foundation program which helps to accelerate research by collecting, storing and providing much-needed human biological samples for use in research. “Our data also confirm the limitations of serology testing in early Lyme disease and after antibiotic treatment.”